2025.12. 31 10年新高,日K线收小阳线,多头韧性但上攻动能减弱,短期调整需求上升。 2470家上涨 2768 涨跌停比 63:13 个股跌多涨少,赚钱效应偏好,盘面上,商业航 天概念延续强势,AI应用方向持续走强,教育、 航空机场、文化传媒等板块涨幅居前:医药商 业、船舶制造、电池、石油、半导体等板块跌幅 居前。 资金情绪 主力资金净流出 397.51 亿元 两市成交额 两市成交额显著缩量,观望情绪浓厚,早盘缩 量明显,午后资金活跃度略有回升但整体偏谨 慎,符合年末"落袋为安"心态,增量资金入场 意愿不强,投资者多以观望为主,市场主要由存 量资金博弈驱动。 散户资金净流入 381.14亿元 机构呈"维稳护盘+跨年布局"的双重特征,对权重股进行护盘操作以稳定指数,借收官窗口调仓换股,主 动加仓AI应用、硬科技等景气赛道,资金逆势净流入布局半导体设备、光伏储能等方向;散户呈"理性乐 观+积极布局"的鲜明特征,对高位题材理性止盈落袋为安,体现风险意识提升;同时,积极抓住年末调仓 窗口,布局商业航天、AI应用、低估值金融等政策支持赛道。 散户情绪 75.85% 让 指 数 3968.84 0 5万亿元 ▼ ...

导读： 创投行业全链条回暖。 作者｜李蕾 来源 ｜每日经济新闻 寒冬退去，暖意渐浓。 2025年，中国创投行业终于走出持续两年的低谷，以"募投管退"全链条回暖的姿态向上回升，行业活力显著修复。政策红利持续释放与退出渠道优化 扩容，为市场注入信心，头部机构的情绪与动作率先回暖。 2025年，顶级市场化VC的投资节奏明显加快，出手频率和金额较上年均有显著提升， 头部机构参投主体数量同比增加16.69% ，资金向优质项目集 中的趋势愈发清晰。从人工智能、半导体到商业航天、生物医药，硬科技赛道成为资本布局的核心主线，创新资产的价值重估正在上演。 资金流向何处，未来就在何方。《每日经济新闻》将 聚焦8家头部市场化VC ，拆解它们在行业回暖周期中的布局逻辑与核心押注的重要项目，从而解 码中国创投行业新一轮发展周期的核心动能。 红杉中国：持续布局硬科技+生物医药，AI成绝对核心 首先来看市场化VC的"老大哥"红杉中国。 今年其实是红杉中国出手持续回暖的第二年。根据记者不完全统计，今年该机构的投资事件数量达到近30次，虽然和前几年的高峰时期不可同日而 语，但与去年、前年同期相比有明显增长。 而从投资金额上来看， 涉及的投资事 ...

Core Insights - The year 2025 marked significant transformations in China's capital market, characterized by index breakthroughs and ecological restructuring, including the Shanghai Composite Index surpassing 4000 points and the handling of the Dongxu Group's 600 billion yuan fraud case [1][10] Group 1: Major Transformations - The most important ideological shift was from "heavy financing" to "coordinated investment and financing," emphasizing a balanced ecosystem and investor returns through improved systems for dividends, buybacks, and mergers [2][12] - A strong consensus emerged around market value management, transitioning from a niche practice to a standard across the market, with 1001 A-share companies disclosing value management systems by November, a fivefold increase from earlier in the year [2][12] Group 2: Key Market Trends - The hottest sectors were AI and hard technology, with the launch of DeepSeek-R1 in January triggering a massive influx of capital into the AI industry chain, leading to a significant revaluation of related stocks [2][13] - A major shift in funding structures occurred, with insurance and social security funds increasing equity asset allocations, and a "deposit migration" trend among residents as savings rates fell below 1% [2][14] Group 3: Regulatory Environment - 2025 was marked by stringent regulatory enforcement, highlighted by the forced delisting of major companies like Dongxu Group for significant fraud, with over 60 companies delisted throughout the year [3][5] - The year also saw a focus on mergers and acquisitions as a strategic solution for asset revaluation, with notable transactions including Guotai Junan's acquisition of Haitong Securities [3][15] Group 4: Notable Reforms - The launch of the "1+6" reform series for the Sci-Tech Innovation Board aimed to enhance the inclusivity and adaptability of the capital market, facilitating the listing of unprofitable companies [5][16] Group 5: Market Performance - The Shanghai Composite Index reached a ten-year high, crossing the 4000-point mark for the first time since August 2015, reflecting a significant recovery in market confidence [6][16] - The total trading volume of A-shares reached a record 29.92 trillion shares, with a total transaction value exceeding 419.86 trillion yuan, marking a 63% increase from 2024 [6][16] Group 6: Unexpected Developments - Hong Kong's stock market made a remarkable comeback, becoming the world's best-performing market with IPO fundraising returning to the top globally and the Hang Seng Index achieving its best annual performance since 2017 [7][17] - The most profitable new stocks were the domestic GPU companies, Moer Thread and Muxi Co., with record profits from initial public offerings, indicating strong market support for domestic GPU alternatives [8][18]

Core Viewpoint - The Hong Kong stock market's Hang Seng Technology Index achieved a remarkable annual increase of 23.45% in 2025, marking its best performance since 2020, with 22 out of 30 constituent stocks rising [1] Group 1: Stock Performance - Among the 30 constituent stocks, notable performers included Hua Hong Semiconductor, which surged by 243.19%, Horizon Robotics with a rise of 140.56%, and SMIC increasing by 124.69% [1] - Other significant gainers were JD Health at 97.51%, Alibaba-W at 77.50%, Xpeng Motors-W at 70.10%, Baidu Group-SW at 59.01%, and Tencent Music-SW at 58.44% [1][2] Group 2: Investment Preferences - The first tier of investment preference is in semiconductor manufacturing (Hua Hong, SMIC) and core AI chips (Horizon Robotics), reflecting a strong focus on hard technology and domestic substitution logic [1] - The second tier includes growth sectors such as smart electric vehicles (Xpeng, Li Auto), AI applications (Baidu, SenseTime), and digital health (JD Health), which benefit from industry trends but still face competitive and profitability uncertainties [1] - The third tier consists of value recovery in platform internet giants (Alibaba, Tencent) and mature applications (NetEase, Kuaishou, Tencent Music), with gains primarily driven by profit realization and value reassessment through dividends and buybacks, categorized as "high-quality mature assets" [1]

Core Insights - The pharmaceutical sector of the Sci-Tech Innovation Board (STAR Market) has shown significant market narrative capabilities and has attracted more attention from the capital market in 2025 [1] - As of December 26, 2025, there were 118 listed companies in the STAR Market's pharmaceutical sector, with 98 companies experiencing stock price increases throughout the year [1] - The number of IPOs for biopharmaceutical companies on the STAR Market has decreased significantly, with only one company, Tianxing Medical, terminating its review in 2025, compared to over 10 in 2024 [2] Market Performance - The STAR Market's overall index has risen by 48.35% since its launch on January 20, 2025, outperforming major broad-based indices [5] - By December 26, 2025, 40 companies in the pharmaceutical sector had stock price increases exceeding 50%, with the top ten companies all surpassing a 100% increase compared to the previous year [6][7] New Listings and Policies - In 2025, five new biopharmaceutical companies were listed on the STAR Market, a significant increase from one in 2024 [2] - The introduction of the "1+6" policy measures by the China Securities Regulatory Commission (CSRC) on June 18, 2025, aimed to enhance the inclusivity of the STAR Market, particularly for unprofitable technology companies [2][3] Company Performance - The top-performing pharmaceutical companies in terms of stock price increase included Tianchen Medical, with a 226.84% rise, and others like Kangzhong Medical and SanSheng Guojian, which also saw significant gains [8] - Many of the companies with the highest stock price increases reported substantial revenue and net profit growth, indicating a strong correlation between financial performance and market valuation [8] Innovation Drug Sector - The innovation drug sector has emerged as a major highlight in 2025, with a total annual increase of 60.75%, driven by supportive policies and increasing market interest [9] - The total amount of business development (BD) transactions in the domestic innovation drug sector exceeded $130 billion in 2025, more than doubling from $64.08 billion in 2024 [10] Challenges in Other Sectors - The IVD (in vitro diagnostics), vaccine, and medical aesthetics sectors faced significant challenges, with many companies experiencing stock price declines and performance pressures [11] - The IVD sector, once considered a golden opportunity, is now facing a downturn due to various factors, including prolonged accounts receivable cycles and lower-than-expected demand [12] - The medical aesthetics industry is also under pressure, with both listed companies reporting declines in performance and stock prices due to increased competition and regulatory changes [13][14]

Group 1 - The core viewpoint of the news highlights the successful completion of the A-share IPO review process for 2025, with a total of 113 companies reviewed and an overall approval rate of 97.35%, reflecting a significant improvement in the quality of applications and regulatory standards [1] - The main board and the ChiNext board showed robust performance, with both the Shanghai main board (19 companies), Shenzhen main board (10 companies), and ChiNext (14 companies) achieving a 100% approval rate, indicating precise support for mature and innovative enterprises [1] - The Beijing Stock Exchange emerged as a key platform for reviewing innovative small and medium-sized enterprises, with 51 companies reviewed and a 96% approval rate, showcasing the continuous release of market vitality [1] Group 2 - The leading underwriting institutions demonstrated a significant "winner-takes-all" effect, with Guotai Junan leading with 16 approved projects, followed by CITIC Securities (12) and CITIC Jianzhong Securities (11), solidifying their positions in the top tier [3] - The distribution of industries indicates a marked improvement in the capital market's service to the real economy, with a concentration of resources in high-tech manufacturing. The computer, communication, and other electronic equipment manufacturing sectors led with 20 companies reviewed, followed by specialized equipment manufacturing (17 companies) [4] - The automotive manufacturing and electrical machinery sectors each had 10 companies reviewed, clearly outlining the financing dominance of "hard technology" and high-end manufacturing, providing strong support for cultivating new productive forces [4]

Summary of Key Points Core Viewpoint - In 2025, 116 companies entered the A-share capital market, raising a total of 131.77 billion yuan, marking a significant increase of 96% compared to the previous year, where 100 companies raised 67.35 billion yuan [1]. Group 1: IPO Financing Overview - The main board accounted for nearly half of the total financing, raising 60.87 billion yuan, while the Sci-Tech Innovation Board raised 38.06 billion yuan, surpassing the Growth Enterprise Market, which raised 25.31 billion yuan. The Beijing Stock Exchange raised 7.53 billion yuan [1]. - A total of 38 companies listed on the main board, 33 on the Growth Enterprise Market, 26 on the Beijing Stock Exchange, and 19 on the Sci-Tech Innovation Board [3]. Group 2: Top IPOs of 2025 - The largest IPO was Huadian New Energy, which raised 18.17 billion yuan, accounting for 13.79% of the total IPO financing for the year. The company is a platform for integrating renewable energy projects [5]. - Other notable IPOs included Moer Thread-U, raising 8 billion yuan, and Xi'an Yicai-U, raising 4.64 billion yuan, both listed on the Sci-Tech Innovation Board [4][5]. Group 3: Market Performance and Trends - Over 70% of companies (85) had IPO financing below 1 billion yuan, while 30 companies raised between 1 billion and 10 billion yuan. Only one company exceeded 10 billion yuan [5]. - The threshold for the top 10 IPO financing in 2025 was 2.71 billion yuan, compared to 1.39 billion yuan in the previous year [6]. - Among the 114 companies that went public, 102 saw their stock prices double on the first day, with five companies experiencing price increases exceeding 500% [6]. Group 4: Notable Stock Price Movements - Dapeng Industrial's stock price surged from an issue price of 9 yuan to a closing price of 118 yuan, with an intraday peak increase of 1666.67% [7]. - Nuxi Co., Ltd. achieved a first-day increase of 692.95%, closing at 829.9 yuan, with a total market value of 332.04 billion yuan [7].

Core Viewpoint - The establishment of various social security science and technology innovation funds across multiple provinces in China, including Sichuan, Zhejiang, and others, aims to support key industries and technological advancements, with a focus on long-term capital and patient investment strategies [3][6][7]. Group 1: Fund Establishment and Scale - The Sichuan Social Security Science and Technology Innovation Fund has an initial scale of 200 billion yuan, focusing on key industries and technological innovation in the Sichuan and Chengdu-Chongqing economic circle [3][4]. - The Zhejiang Social Security Science and Technology Innovation Fund has a larger initial scale of 500 billion yuan, targeting sectors such as artificial intelligence and biomedicine [5]. - The combined initial scale of social security science and technology innovation funds in five regions, including Zhejiang, Jiangsu, Fujian, Hubei, and Sichuan, has reached 1.6 trillion yuan [6]. Group 2: Long-term Investment Strategies - Sichuan's measures emphasize the importance of "patient capital," which is characterized by long-term support and a high tolerance for risk and failure, aligning with the long growth cycles of technology companies [6][9]. - The government aims to attract social capital by implementing a profit-sharing model between government-guided funds and market-oriented funds, with a focus on long-term investment horizons [8][10]. Group 3: Policy and Regulatory Framework - The Sichuan government has set ambitious targets, including a goal of 4 trillion yuan in fund management scale by 2030, and has introduced specific measures to enhance the investment environment for venture capital [8][10]. - Recent national policies encourage the relaxation of restrictions on government investment funds, promoting a more open and pragmatic approach to fund management and investment [10][12]. - The average return ratio requirement for government-guided funds has decreased significantly, with many funds now allowing for lower return expectations, reflecting a shift towards more flexible investment strategies [11][12]. Group 4: Risk Tolerance and Investment Focus - The Sichuan policy allows for a maximum loss tolerance of 100% for individual projects, indicating a willingness to support high-risk, high-reward investments in emerging technologies [13][14]. - The focus on hard technology investments has shifted the venture capital landscape, necessitating a longer investment horizon and a more patient approach from both general partners (GPs) and limited partners (LPs) [9][10].

逐光硬科技，A股前十大IPO背后的资本叙事 2025年的A股资本市场，硬科技无疑是最耀眼的时代注脚。 摩尔线程、沐曦股份的股价在科创板开盘后上演"直线飙升"的狂欢，天有为作为东三省的"独苗"在主板稳健起航，这些镌刻着"国产替代"鲜明印记的企 业，不仅以高发行价强势跻身年度前十大IPO榜单，更在背后串联起超百家投资机构的"逐光之路"。 Wind数据显示，摩尔线程、沐曦股份、天有为、优优绿能等十家企业凭借高发行价跻身前列。 融中整理发现，这些项目背后，背后汇聚了超百家投资机构的身影。 在这份长长的投资机构名单中，联想创投上演帽子戏法，分别投资了摩尔线程、沐曦股份、昂瑞微电子。 此外，红杉中国、前海母基金、深创投、建银国际、中关村科学城、万石创投、海达投资、哈勃投资、丰年资本、追远创投、小米、中信证券投资、图灵 资管、中卫颐和、泰达科投等投资机构分别拿下两家。 这份年度榜单，绝非简单的资本市场融资答卷，而是一段段资本与硬科技企业相互成就、穿越技术攻坚"死亡谷"的成长史诗。而这十家发行价"王者"项 目，也勒出A股资本市场的融资新图景。 融中财经整理发现，在2025年A股前十大IPO（按发行价计）的资本版图中，联想创投 ...

Core Viewpoint - Changxin Technology Group Co., Ltd. plans to go public on the Sci-Tech Innovation Board, aiming to raise 29.5 billion yuan, potentially becoming the first domestic storage stock in A-shares, drawing significant attention to the development of China's hard technology industry [1][4]. Group 1: Company Overview - Changxin Technology is the largest and most advanced DRAM (Dynamic Random Access Memory) research, design, and manufacturing enterprise in China, ranking first in production capacity domestically and fourth globally [4]. - The company has received approval for its IPO, with China International Capital Corporation and CITIC Securities as its sponsors, and Deloitte Huayong as its accounting firm [3]. Group 2: Market Positioning - The timing of Changxin's IPO is strategic, addressing a structural gap in China's semiconductor industry and capital market, particularly in the high-tech and capital-intensive storage chip manufacturing sector [4]. - The company aims to fill a critical void in the domestic semiconductor market, where no local leading firm has been publicly listed in the storage chip manufacturing domain [4]. Group 3: Research and Development - From 2022 to the first half of 2025, Changxin Technology's cumulative R&D investment reached 18.867 billion yuan, accounting for 33.11% of its total revenue, with an R&D expense ratio of 23.71% in the first half of 2025, significantly exceeding the industry average [5]. - The company plans to launch advanced products such as LPDDR5X and DDR5, with LPDDR5X achieving a maximum speed of 10,667 Mbps, a 66% increase over the previous generation, and its first domestic DDR5 product reaching speeds of 8,000 Mbps with a maximum capacity of 24Gb [5][7]. Group 4: Client Base and Market Impact - Changxin Technology's products are well-received in the market, with clients including major companies like Alibaba Cloud, ByteDance, Tencent, Lenovo, Xiaomi, Transsion, Honor, OPPO, and vivo, demonstrating its strong market presence [7]. - The company is positioned as a key player in the semiconductor supply chain, contributing to the self-sufficiency of China's semiconductor industry through its technological advancements and market penetration [7]. Group 5: Future Outlook - The IPO of Changxin Technology signifies a transition for the domestic high-end storage industry from technological challenges to a comprehensive test in the capital market, providing a broader financing platform while facing increased public scrutiny [8]. - The success of the fundraising is seen as just the beginning, with the real challenge lying in leveraging capital to achieve sustainable technological breakthroughs and commercial success amid global competition and industry cycles [8].